560 related articles for article (PubMed ID: 8603034)
1. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
[TBL] [Abstract][Full Text] [Related]
3. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
4. Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
Mahler C; Verhelst J; Denis L
Cancer; 1993 Feb; 71(3 Suppl):1068-73. PubMed ID: 8428329
[TBL] [Abstract][Full Text] [Related]
5. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
7. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
10. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Barrie SE; Potter GA; Goddard PM; Haynes BP; Dowsett M; Jarman M
J Steroid Biochem Mol Biol; 1994 Sep; 50(5-6):267-73. PubMed ID: 7918112
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy of prostate cancer.
Bare RL; Torti FM
Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda M; Hosaka M
Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
[No Abstract] [Full Text] [Related]
14. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
15. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
[TBL] [Abstract][Full Text] [Related]
16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
17. Adrenal androgen blockade in relapsed prostate cancer.
Geller J; Albert JD
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1127-31. PubMed ID: 2934257
[TBL] [Abstract][Full Text] [Related]
18. Liarozole.
Bryson HM; Wagstaff AJ
Drugs Aging; 1996 Dec; 9(6):478-84; discussion 485. PubMed ID: 8972247
[TBL] [Abstract][Full Text] [Related]
19. Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha).
Sergejew T; Hartmann RW
J Enzyme Inhib; 1994; 8(2):113-22. PubMed ID: 7539071
[TBL] [Abstract][Full Text] [Related]
20. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
